Тромбофилия (8 маркеров), кровь

Genetic Risk of Thrombophilia (Expanded) is a multi‑gene DNA panel that evaluates inherited predisposition to pathologic clotting by interrogating variants across coagulation factors, platelet receptors, the fibrinolytic pathway, and folate metabolism. The test supports assessment of venous and, in some settings, arterial thrombotic risk in individuals with personal or family histories of thromboembolism, early‑onset or recurrent thrombosis, pregnancy morbidity, or before exposures such as estrogen therapy, major surgery, or prolonged immobilization. Common synonyms include inherited thrombophilia panel and thrombophilia DNA panel. Results can inform prevention and management strategies, including risk counseling prior to hormonal therapy or high‑risk procedures and consideration of antithrombotic prophylaxis in appropriate clinical contexts. Genotyping of ITGB3 (T1565C) may also provide insight into the likelihood of response to aspirin therapy when antiplatelet treatment is being considered.

Hereditary thrombophilia reflects genetic changes that shift hemostasis toward clot formation by altering components of coagulation, platelet function, fibrinolysis, or folate metabolism. In physiologic conditions, procoagulant and anticoagulant forces are balanced; inherited variants can disrupt this equilibrium and, when combined with acquired stressors, increase thrombotic risk. The panel targets key markers, including F5 G1691A (Arg506Gln, Leiden) which confers activated protein C resistance and accelerates thrombin generation, and F2 G20210A which elevates prothrombin production. Additional loci include FGB G(−455)A, associated with higher fibrinogen levels and peripheral or coronary thrombosis; F13A1 G103T (Val34Leu) and F7 G10976A (Arg353Gln); platelet receptor genes ITGA2 C807T and ITGB3 T1565C (Leu59Pro), which influence platelet adhesion/aggregation and may relate to aspirin effect; and the fibrinolysis regulator SERPINE1 (PAI‑1) −675 5G>4G, where the unfavorable allele is linked to reduced fibrinolytic activity and thromboembolic complications. Variants in folate‑cycle enzymes, particularly MTHFR C677T (Ala222Val) and A1298C (Glu429Ala), can reduce enzyme activity and promote hyperhomocysteinemia. Elevated homocysteine exerts endothelial toxicity, fosters vascular injury, and contributes to atherothrombosis in both arterial and venous beds. Beyond thrombosis, carriers of these changes—along with F5 and F2 variants—may experience adverse pregnancy outcomes such as recurrent pregnancy loss and fetal growth restriction. When folate metabolism is impaired, preventive measures with folic acid and vitamins B6 and B12 may be considered; duration and dosing can be individualized according to genotype, homocysteine concentration, and coexisting risk factors. Genetic risk is often unmasked by acquired triggers. Factors that heighten thrombotic risk include bed rest exceeding three days, prolonged immobilization, sustained static postures or low activity, estrogen‑containing oral contraceptives, obesity, prior venous thromboembolism, central venous catheterization, dehydration, surgery, trauma, smoking, malignant neoplasms, pregnancy, and coexisting cardiovascular disease. Knowledge of genotype allows clinicians to calibrate surveillance and prophylaxis strategies before high‑risk exposures and across the reproductive timeline.